TCTR20240711001Not yet recruitingPhase 3
Efficacy of CYTISINE for Smoking Cessation through Downward Titration versus Simplified Three times daily Regimen : Open-label Randomized Clinical Trial
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to 65 Years (—)
- Sex
- All
Inclusion Criteria
- •1. Over 18 years of age and not over 65 years of age.
- •2. Current daily cigarette smokers. There is a need to quit smoking at the preparation/contemplation level according to The Trans theoretical Model.
- •3. Sign the Informed Consent Form.
- •4. Smoke more than 10 cigarettes per day.
- •5. If you are a woman of reproductive age and have a chance of becoming pregnant Must be willing to use birth control before participating in the research project. 6. Have a mobile phone that can set reminders and allow the use of telephone reminder methods. For use in evaluating drug compliance of volunteers
Exclusion Criteria
- •1. Have a congenital disease that may be dangerous from receiving research drugs, such as heart arrhythmia. Coronary artery disease, cancer, chronic kidney disease (creatinine clearance <30 ml/minute), psychiatric disorders such as depression. schizophrenia or patients who also use other types of drugs such as marijuana, amphetamines, etc.
- •2. Are pregnant or breastfeeding
- •3. Already being treated with medications to help you quit smoking, including nicotine replacement therapy (NRT), Nortriptyline, Bupropion, Clonidine, and Varenicline.
Investigators
Similar Trials
Not yet recruiting
Phase 2
Cytisine versus nicotine for smoking cessation in hospitalized psychiatric patients.IRCT20100127003210N16Shahid Beheshti University of Medical Sciences60
Completed
Phase 1
Cytisine as a smoking cessation aid: measuring blood levels, craving, withdrawal and mood over a course of treatmentSmokingOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)ACTRN12613000002785niversity of Auckland12
Active, not recruiting
Phase 1
Comparison of Varenicline and Cytisine effectiveness on nicotine smoking cessation in Primary health care - randomized controlled trialTobacco addictionEUCTR2019-003720-20-SIniversity of Zagreb School of Medicine380
Recruiting
Not Applicable
Analysis and Evaluation of Smoking Treatment With CytisineModerate or Severe Tobacco Use DisorderNCT06439303Regina Elena Cancer Institute65
Active, not recruiting
Phase 1
Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center, randomized, non-inferiority clinical trial.icotine dependence, Chronic Kidney DiseaseMedDRA version: 20.0Level: PTClassification code: 10057852Term: Nicotine dependence Class: 100000004873MedDRA version: 21.1Level: PTClassification code: 10064848Term: Chronic kidney disease Class: 100000004857CTIS2023-509235-39-00arodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy292